Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Unity Biotechnology, Inc. $85 Million Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 5…
Ping An Healthcare and Technology Company Limited HK$8.77 Billion ($1.12 Billion) Initial Public Offering
Davis Polk advised the joint global coordinators in the Hong Kong initial public offering of Ping An Healthcare and…
Trident Clinical Services Holdings credit agreements amendment
We advised the agent in connection with an amendment
Davis Polk Advises McKesson on Its Acquisition of Medical Specialties Distributors
Davis Polk is advising McKesson Corporation on its acquisition of Medical Specialties Distributors, LLC from New Mountain…
Davis Polk Advises Notre Dame Intermédica on Its R$2.4 Billion Initial Public Offering
Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the initial public offering by Notre Dame…
Aeglea BioTherapeutics $36 Million Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $36 million SEC-registered common stock…
Shire $2.4 billion sale of its Oncology business to Servier
Davis Polk is advising Shire plc on the $2.4 billion sale of its Oncology business to Servier S.A.S. The transaction has…
Cellectis S.A. Follow-On Offering
Davis Polk advised the representatives of the underwriters in connection with the $175 million public offering by Cellectis…
PTC Therapeutics, Inc. Common Stock Offering
Davis Polk advised the lead book-running managers and representatives of the underwriters in connection with the SEC…
Davis Polk Advises Charles River Laboratories International, Inc. on Its $500 Million Notes Offering
Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of …